Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATTO-1091 · 1 trial · 1 indication
The primary analysis will describe the incidence of AEs and laboratory abnormalities. AEs will be coded according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA, version 28.0 or the current version). Their severity will be graded using the NCI CTCAE v5.0 or the current version.
Clinical laboratory parameters (hematologic and blood chemistry) will be summarized by visit
ECG findings (including QT abnormalities) will be summarized by visit.
Vital signs (systolic and diastolic blood pressure, temperature, heart rate) will be summarized by visit.
| Arm | Type | Description |
|---|---|---|
| ATTO-1091 Single dose SC | EXPERIMENTAL | ATTO-1091 Dose level cohorts receiving a single dose SC |
| ATTO-1091 Multiple dose SC | EXPERIMENTAL | ATTO-1091 Dose level cohorts receiving multiple SC doses |
| Placebo single dose SC | EXPERIMENTAL | Placebo preparation to match Experimental Arm with single dose SC |
| Placebo multiple dose SC | EXPERIMENTAL | Placebo preparation to match Experimental Arm administered in multiple SC doses |
| Name | Type | Description |
|---|---|---|
| ATTO-1091 | DRUG | ATTO-1091 |
| Placebo | DRUG | Placebo preparation to match ATTO-1091 dose |
Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria: * Any sex or gender who is 18 to 60 years old, inclusive, at Screening. * Body weight of 45 to 125 kg, inclusive, and body mass index (BMI) between 18.5 and 35 kg/m2. * Considered in good general health based on medical history, physical exam,...
Top 15 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug, SAR441566, Dupilumab, SAR443122, balinatunfib |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab, Tirzepatide, MORF-057, LY4395089, Eltrekibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab, Zasocitinib |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab, Guselkumab, Golimumab, Infliximab, Icotrokinra |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib, Risankizumab, Lutikizumab, Adalimumab |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart, MK-8690 |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod, tofacitinib |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib, Tilpisertib Fosmecarbil, emvistegrast |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |